Movement Alert｜Innovent Biologics Falls 3.04% in Regular Trading, Pfizer Deal Regulatory Uncertainty and Biotech Sector Selloff Weigh on Shares

Market Focus06-03

On June 3, Innovent Biologics fell 3.04% in regular trading, trading at HKD 76.45/share, with trading volume of HKD 242 million. The stock has declined for multiple consecutive sessions after surging over 11% on May 29 following the announcement of a $10.5 billion global strategic collaboration with Pfizer.

On the news front, market concerns persist over whether the transaction can secure regulatory approval. Recent discussions surrounding potential revisions to biomedical export control lists and the U.S. COINS Act, which may impose restrictions on cross-border biotech collaborations, have intensified uncertainty and suppressed investor sentiment.

Meanwhile, the broader biotech sector continued its weak performance, with AKESO down 4.04%, REMEGEN down 4.04%, 3SBIO down 3.38%, EVEREST MED down 2.69%, and BEIGENE down 2.67%, creating systematic selling pressure that further weighed on Innovent Biologics through sector-wide contagion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128322453?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128322453","market":"us","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Falls 3.04% in Regular Trading, Pfizer Deal Regulatory Uncertainty and Biotech Sector Selloff Weigh on Shares","media":"Market Focus","content":"<p><p>On June 3, Innovent Biologics fell 3.04% in regular trading, trading at HKD 76.45/share, with trading volume of HKD 242 million. The stock has declined for multiple consecutive sessions after surging over 11% on May 29 following the announcement of a $10.5 billion global strategic collaboration with Pfizer.</p><p>On the news front, market concerns persist over whether the transaction can secure regulatory approval. Recent discussions surrounding potential revisions to biomedical export control lists and the U.S. COINS Act, which may impose restrictions on cross-border biotech collaborations, have intensified uncertainty and suppressed investor sentiment.</p><p>Meanwhile, the broader biotech sector continued its weak performance, with AKESO down 4.04%, REMEGEN down 4.04%, 3SBIO down 3.38%, EVEREST MED down 2.69%, and BEIGENE down 2.67%, creating systematic selling pressure that further weighed on Innovent Biologics through sector-wide contagion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Falls 3.04% in Regular Trading, Pfizer Deal Regulatory Uncertainty and Biotech Sector Selloff Weigh on Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Falls 3.04% in Regular Trading, Pfizer Deal Regulatory Uncertainty and Biotech Sector Selloff Weigh on Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-03 10:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 3, Innovent Biologics fell 3.04% in regular trading, trading at HKD 76.45/share, with trading volume of HKD 242 million. The stock has declined for multiple consecutive sessions after surging over 11% on May 29 following the announcement of a $10.5 billion global strategic collaboration with Pfizer.</p><p>On the news front, market concerns persist over whether the transaction can secure regulatory approval. Recent discussions surrounding potential revisions to biomedical export control lists and the U.S. COINS Act, which may impose restrictions on cross-border biotech collaborations, have intensified uncertainty and suppressed investor sentiment.</p><p>Meanwhile, the broader biotech sector continued its weak performance, with AKESO down 4.04%, REMEGEN down 4.04%, 3SBIO down 3.38%, EVEREST MED down 2.69%, and BEIGENE down 2.67%, creating systematic selling pressure that further weighed on Innovent Biologics through sector-wide contagion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1128322453","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128322453","pubTimestamp":1780452102,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 3, Innovent Biologics fell 3.04% in regular trading, trading at HKD 76.45/share, with trading volume of HKD 242 million. The stock has declined for multiple consecutive sessions after surging...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动向提示|信达生物常规交易跌3.04%辉瑞交易监管不确定性及生物科技板块抛售令股价承压","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 3, Innovent Biologics fell 3.04% in regular trading, trading at HKD 76.45/share, with trading volume of HKD 242 million. The stock has declined for multiple consecutive sessions after surging over 11% on May 29 following the announcement of a $10.5 billion global strategic collaboration with Pfizer.On the news front, market concerns persist over whether the transaction can secure regulatory approval. Recent discussions surrounding potential revisions to biomedical export control lists and the U.S. COINS Act, which may impose restrictions on cross-border biotech collaborations, have intensified uncertainty and suppressed investor sentiment.Meanwhile, the broader biotech sector continued its weak performance, with AKESO down 4.04%, REMEGEN down 4.04%, 3SBIO down 3.38%, EVEREST MED down 2.69%, and BEIGENE down 2.67%, creating systematic selling pressure that further weighed on Innovent Biologics through sector-wide contagion.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128322453","isCrawlerRequest":true}